Steroid-dependent Crohn’s disease is a challenging condition that requires careful management. The following approaches are recommended for treating steroid-dependent Crohn’s disease:
Immunomodulators
Azathioprine (AZA) and 6-mercaptopurine (6-MP) are effective options for maintaining remission in steroid-dependent Crohn’s disease:
- These drugs allow for steroid tapering and withdrawal
- They can maintain steroid-free remission in many patients
- Thiopurine (Azathioprin/6-Mercaptopurin):
- Dosierung: Azathioprin 2,0-2,5 mg/kg KG/Tag oder 6-Mercaptopurin 1,0-1,5 mg/kg KG/Tag
- Nicht zur Remissionsinduktion geeignet
- Remissionserhaltung: 73% vs. 62% Placebo (nach 6-18 Monaten)
- Dosierungsstrategie: Abwägung zwischen schneller vs. langsamer Aufdosierung
- Methotrexat (MTX):
- Induktion: 25 mg/Woche für 16 Wochen
- Erhaltung: 15 mg/Woche
- Remissionsraten: 39,4% vs. 19,1% Placebo
- Remissionserhalt: 65% vs. 39% Placebo
- Wichtig: Folsäuresubstitution, subkutane Applikation bevorzugt
Biologic Therapies
Anti-TNF agents are highly effective for inducing and maintaining remission:
- Infliximab, adalimumab, and other anti-TNF drugs are recommended
- They are more effective than azathioprine/6-MP alone for achieving steroid-free remission
Combination Therapy
Combining an immunomodulator with an anti-TNF agent is superior to either alone:
- Infliximab plus azathioprine is more effective than azathioprine alone for steroid-dependent patients
- This combination achieves higher rates of steroid-free remission
Other Biologic Options
For patients who fail or cannot tolerate anti-TNF therapy, other biologics may be considered:
- Ustekinumab
- Vedolizumab
- Risankizumab
Methotrexate
Methotrexate is recommended for maintaining remission in steroid-dependent Crohn’s disease, particularly when administered parenterally.
Steroid-Sparing Strategies
The goal is to achieve and maintain steroid-free remission:
- Tapering steroids while initiating immunomodulators or biologics
- Using budesonide instead of systemic steroids when possible for ileal/right-sided colonic disease
- Avoiding repeated or prolonged steroid courses
Monitoring and Follow-up
Regular assessment is crucial:
- Monitor for clinical response and remission
- Evaluate steroid-free remission rates
- Assess mucosal healing through endoscopy
- Monitor for potential side effects of immunosuppressive therapies
Surgery
In cases refractory to medical management, surgery may be necessary:
- Ileocecal resection can be considered for localized disease
- Early surgical intervention may lead to improved outcomes in some patients
The treatment approach should be individualized based on disease characteristics, previous treatment response, and patient preferences. The goal is to induce and maintain steroid-free remission while minimizing complications and improving quality of life.